We are excited to present Abecma, a groundbreaking CAR-T cell therapy for the treatment of multiple myeloma. Developed by China-based biotechnology company Beijing BIOOCUS Biotech Ltd., Abecma has shown unprecedented results in clinical trials, leading to its approval as the first CAR-T cell therapy for multiple myeloma by the China National Medical Products Administration (NMPA), Abecma harnesses the power of a patient's own immune system to target and attack cancer cells. By genetically modifying the patient's T-cells to express a chimeric antigen receptor (CAR) that targets the B-cell maturation antigen (BCMA) found on myeloma cells, Abecma offers a personalized and targeted approach to treatment
Please feel free to give your inquiry in the form below We will reply you in 24 hours